Literature DB >> 9918128

Nomenclature for human DPYD alleles.

H L McLeod1, E S Collie-Duguid, P Vreken, M R Johnson, X Wei, A Sapone, R B Diasio, P Fernandez-Salguero, A B van Kuilenberg, A H van Gennip, F J Gonzalez.   

Abstract

To standardize DPYD allele nomenclature and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that each distinct allele be designed by DPYD followed by an asterisk and an Arabic numeral. The number specifies the key mutation and, where appropriate, a letter following the number indicates an additional mutation on the mutant allele. Criteria for classification as a distinct allele are also presented.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9918128     DOI: 10.1097/00008571-199812000-00001

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  12 in total

1.  Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.

Authors:  Timur Cerić; Nermina Obralić; Lejla Kapur-Pojskić; Drazenka Macić; Semir Beslija; Anes Pasić; Sejla Cerić
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

Review 2.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  Interaction between capecitabine and brivudin in a patient with breast cancer.

Authors:  José M Baena-Cañada; María J Martínez; Obdulia García-Olmedo; Reyes Jiménez-Bárcenas; Pedro Muriel-Cueto
Journal:  Nat Rev Clin Oncol       Date:  2010-01       Impact factor: 66.675

4.  PharmGKB summary: fluoropyrimidine pathways.

Authors:  Caroline F Thorn; Sharon Marsh; Michelle Whirl Carrillo; Howard L McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-04       Impact factor: 2.089

5.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Authors:  Keiko Maekawa; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kouichi Kurose; Nahoko Kaniwa; Manabu Kawamoto; Naoyuki Kamatani; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao; Yasuhiro Shimada; Manabu Muto; Toshihiko Doi; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  J Hum Genet       Date:  2007-09-09       Impact factor: 3.172

Review 6.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

7.  DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.

Authors:  Hong Zhang; You-ming Li; Hao Zhang; Xi Jin
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

8.  Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China.

Authors:  Xin Zhang; Butong Sun; Zhenxia Lu
Journal:  Int J Med Sci       Date:  2013-05-20       Impact factor: 3.738

Review 9.  Cancer pharmacogenetics.

Authors:  S Marsh; H L McLeod
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

10.  Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.

Authors:  Joong-Gon Shin; Hyun Sub Cheong; Jason Yongha Kim; Lyoung Hyo Kim; Chang Soo Han; Ji On Kim; Hae Deun Kim; Young Hoon Kim; Myeon Woo Chung; Soon Young Han; Hyoung Doo Shin
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.